Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil alone is often insufficient for significant hair regrowth, with many users experiencing limited results or side effects, leading them to add finasteride or dutasteride for better outcomes. Some users report initial improvements with minoxidil but eventually require additional treatments to maintain or enhance hair growth.

PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

Red flags to watch for when choosing a hair transplant clinic, such as high-pressure sales tactics, unclear surgeon assignments, and unrealistic promises. A user shared a positive experience with Skin Medics UK, highlighting transparency and personalized care.

The user experienced severe sexual side effects from topical finasteride with minoxidil but found no side effects with low-dose dutasteride and finasteride serums from Ulo after a hair transplant. They also used a hair growth serum with saw palmetto without side effects.

The user is experiencing gradual hair growth using 5% minoxidil, 0.01% finasteride, vitamins, capixyl serum, niacin, and weekly microneedling, with plans to increase finasteride dosage. Despite some side effects, they remain optimistic about hair transplant results, focusing on the crown and temples.

Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

Bee venom at 0.001% concentration was more effective than 2% minoxidil in promoting hair growth in mice, possibly due to increased growth factors and reduced inflammation. Caution is advised due to potential allergic reactions and the reliance on animal data.

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

A 16-year-old experiencing diffuse hair thinning is considering using minoxidil and plans to start finasteride at 18, while others suggest alternatives like saw palmetto and pumpkin seed oil. Users advise consulting a doctor before starting treatments and emphasize the importance of understanding the cause of hair loss.

Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.

A 20-year-old is experiencing hair thinning and seeks advice on starting treatment and regrowing hair. They are considering using Minoxidil, finasteride, or RU58841.

People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.

The user is taking dutasteride 0.5mg daily and seeks a topical androgen inhibitor for the scalp. They are looking for recommendations to enhance their hair loss treatment.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Alternatives to finasteride for hair loss include minoxidil, alfatrodial, fluridil, pyrilutamide, and Nizoral. These treatments may not be as effective as finasteride but can help slow hair loss progression.

Dutasteride at 0.5mg may have fewer sexual side effects than expected, with many side effects attributed to psychological factors (nocebo effect). The placebo group experienced more side effects, suggesting fear and anxiety might contribute to perceived side effects.

A 31-year-old man with androgenic alopecia is considering treatments like finasteride, minoxidil, and ketoconazole shampoo but is worried about finasteride's side effects. Users recommend starting with finasteride or dutasteride for DHT blocking, suggesting topical solutions to reduce side effects.

The user is experiencing increased hair thinning and shedding despite using oral dutasteride, oral minoxidil, topical dutasteride, and ketoconazole shampoo. Many recommend considering a hair transplant or embracing baldness, as current treatments seem ineffective.

The user added topical minoxidil to their finasteride regimen, resulting in healthier hair and some regrowth, especially after quitting nicotine. They experienced minimal shedding and noted improvements in hairline density, finding the treatment mostly preventative.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

OP shares their experience with PCOS-related hair loss, highlighting that addressing vitamin D and ferritin deficiencies, managing hormones with spironolactone, and using gentle hair care products helped improve their condition. They advise against relying on "miracle" hair oils and emphasize the importance of medical evaluation and a combined approach to treatment.

A homemade topical solution of finasteride and minoxidil effectively stopped hair shedding and promoted regrowth without side effects. Users shared experiences and discussed different concentrations and application methods.

Rotenone, a natural plant extract, may promote hair growth by increasing LDH activity and blocking MPC in the scalp, but it carries risks due to its toxicity. The suggested formulation includes Barbasco extract, DMSO, propylene glycol or PEG-400, ethanol, and a carrier oil.

The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.

A British man's death at a Turkish hair transplant clinic raised safety concerns about such clinics. Users discussed risks of cheaper clinics and suggested alternatives like Thailand, Korea, and Colombia.

A user from France is seeking ways to obtain oral minoxidil in the EU without a prescription, as local doctors are hesitant to prescribe it. Suggestions include visiting Spain for a prescription, ordering online, or consulting doctors in other EU countries like Portugal.

A 23-year-old man uses a topical spray with minoxidil, finasteride, and tretinoin for hair loss, experiencing improved hair growth but occasional heart palpitations. He worries his girlfriend might leave him if he goes bald, but commenters advise that if she would leave over hair loss, she isn't worth it.

Hair loss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stem cell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.